About 71% of U.S. adults are either overweight or obese, according to the Centers for Disease Control. That makes it easy to ...

Q. I took Wegovy for a few months last fall until I was unable to find a pharmacy that could fill my prescription. They were ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in individuals aged 12 ...

Therefore, an alternative drug may be preferable. Some people may experience unpleasant side effects when taking Wegovy. If this occurs, a doctor may suggest trying an alternative medication.

Also, Wegovy is currently approved by the FDA to help lower the risk of heart attacks and strokes. Zepbound doesn’t have that approval, at least not yet. So, no one should stop taking or change ...

For the study, researchers randomly assigned 751 participants with obesity but not Type 2 diabetes to take either tirzepatide, aka Zepbound, or semaglutide, aka Wegovy, weekly, for 72 weeks.

People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s Wegovy. According to a study funded by Eli Lilly, the trial revealed that ...

Luckily, I had no side effects at all while taking Wegovy. I have since lost 30 lbs ... We agree that researchers should explore this potential benefit of GLP-1-type drugs for addictions.